TY - JOUR T1 - Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray JF - bioRxiv DO - 10.1101/2020.04.15.043364 SP - 2020.04.15.043364 AU - Rafael R. de Assis AU - Aarti Jain AU - Rie Nakajima AU - Algis Jasinskas AU - Jiin Felgner AU - Joshua M. Obiero AU - Oluwasanmi Adenaiye AU - Sheldon Tai AU - Filbert Hong AU - Philip Norris AU - Mars Stone AU - Graham Simmons AU - Anil Bagri AU - Martin Schreiber AU - Andreas Buser AU - Andreas Holbro AU - Manuel Battegay AU - Donald K. Milton AU - Prometheus Study Group AU - Huw Davies AU - Laurence M. Corash AU - Michael P. Busch AU - Philip L. Felgner AU - Saahir Khan Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/04/17/2020.04.15.043364.abstract N2 - The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates complete discrimination of these two groups. This array can be used as a diagnostic tool, as an epidemiologic tool to more accurately estimate the disease burden of COVID-19, and as a research tool to correlate antibody responses with clinical outcomes.Competing Interest StatementThe coronavirus antigen microarray is intellectual property of the Regents of the University of California that is licensed for commercialization to Nanommune Inc. (Irvine, CA), a private company for which Philip L. Felgner is the largest shareholder and several co-authors (de Assis, Jain, Nakajima, Jasinskas, Obiero, Davies, and Khan) also own shares. Nanommune Inc. has a business partnership with Sino Biological Inc. (Beijing, China) which expressed and purified the antigens used in this study. The convalescent plasma used in this study was collected for clinical use by independent blood centers using licensed plasma or platelet processing systems manufactured by Cerus Corporation, for which multiple authors (Corash, Bagri) are shareholders and employees. ER -